Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Head and Neck Neoplasms 2Gliosarcoma 2Glioma 2Colorectal Neoplasms 2Breast Neoplasms 2Brain Neoplasms 2Supratentorial Neoplasms 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Oligodendroglioma 1Neoplasm Metastasis 1Lung Neoplasms 1Liver Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Bronchiolitis Obliterans Syndrome 1Astrocytoma 1

Interventions

Sorafenib 42Bevacizumab 26Oxaliplatin 21Radiosurgery 19Gemcitabine 17Fluorouracil 15Hepatectomy 13lenvatinib 12Radiofrequency Ablation 11Nivolumab 11Cisplatin 11Radiotherapy 10Doxorubicin 10Capecitabine 10durvalumab 9Leucovorin 9Blood Specimen Collection 9atezolizumab 8Liver Transplantation 8Everolimus 7Electroporation 7pembrolizumab 6camrelizumab 6Sunitinib 6Immunohistochemistry 6Cryosurgery 6Carboplatin 6tremelimumab 5sintilimab 5apatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Liver Neoplasms × lonafarnib × Clear all
NCT00020774 2020-07-31

SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡